748154-34-9

Upstream product

• 748154-36-1 5-methyl-4-[2-(2-methyl-3-nitrophenoxy)ethyl]-2-phenyl-1,3-oxazole 
• 103788-64-3 methyl 2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)acetate 
• 105983-77-5 methyl 4-bromo-3-oxopentanoate 
• 748154-35-0 2-methyl-3-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]aniline 

Downstream Products

• 748154-38-3 ethyl {4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2H-indazol-1-yl}acetate 
• 748154-37-2 ethyl {4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1H-indazol-1-yl}acetate 

Relevant academic research and scientific papers

Process development and scale-up of AG035029

A practical process for the synthesis of PPARγ agonist AG035029 was developed which involved six steps along the longest linear path. The process development utilized automated technology and computational chemistry extensively to accelerate the speed of

OXAZOLE-DERIVATIVES AS PPAR AGONISTS

Fused heteroaryl carboxylic acids of formula (I): wherein R1, Ar, A, Y, HET, Q, and T are as defined in the specification; pharmaceutical compositions containing effective amounts of said compounds or their salts are useful for treating PPAR related disorders, such as diabetes, dyslipidemia, obesity and inflammatory disorders.